Get started
Author

Jeppe Klint Buchbjerg

Observed names: J Buchbjerg, J. Buchbjerg, Jeppe Buchberg, Jeppe Buchbjerg
Institution: Genmab (Denmark)
OpenAlex ID: A5072476751
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
2017 · Enrico Bertini, Eric Dessaud, et al. · The Lancet Neurology · 122
PDF
Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
2013 · Grace Chen, Ronald Lee, et al. · Clinical Drug Investigation · 106
PDF
Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls
2017 · J Smith, M Browning, et al. · Molecular Psychiatry · 93
PDF
Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study
2022 · Kan Yonemori, Yasutoshi Kuboki, et al. · Cancer Science · 35
Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men
2015 · Sue Wilson, Astrid-Maria Højer, et al. · Journal of Psychopharmacology · 32
PDF
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma
2023 · Koji Izutsu, Takahiro Kumode, et al. · Cancer Science · 31
PDF
Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)
2019 · Eugenio Mercuri, Giovanni Baranello, et al. · Neurology · 13
A randomized, placebo-controlled, double-blind, Phase 1b/2 study of the novel antimyostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy (P5.431)
2018 · Kathryn Wagner, Brenda Wong, et al. · Neurology · 5
P.2.f.014 Effects of vortioxetine on resting-state activity in subjects remitted from depression and healthy controls
2015 · S. Conen, S. McKie, et al. · European Neuropsychopharmacology · 5
P.1.g.013 Effects of vortioxetine versus paroxetine on polysomnography in man: a pharmacokinetic/pharmacodynamic study
2013 · S. Wilson, J. Buchbjerg, et al. · European Neuropsychopharmacology · 4
Sma Therapies Ii and Biomarkers
2018 · E. Mercuri, G. Baranello, et al. · Neuromuscular Disorders · 2
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects
2018 · Uwe Schuehly, Surya Ayalasomayajula, et al. · European Journal of Clinical Pharmacology · 2
A Long-Term, Open-Label Follow-Up Study of Olesoxime in Patients with Type 2 or Non-Ambulatory Type 3 Spinal Muscular Atrophy who Participated in a Placebo-Controlled Phase 2 Trial (S46.002)
2018 · Francesco Muntoni, Jeppe Buchbjerg, et al. · Neurology · 2
P.1.i.026 Vortioxetine reduces BOLD signal during performance of the N-back task in subjects remitted from depression and healthy control participants
2015 · M. Browning, J. Smith, et al. · European Neuropsychopharmacology · 2
Vortioxetine Reduces BOLD Signal during Performance of the N-Back Task in Subjects Remitted from Depression and Healthy Control Participants
2014 · Michael Browning, John A. Smith, et al. · Neuropsychopharmacology · 2
Olesoxime in patients with type 2 or non-ambulatory type 3 Spinal muscular atrophy: a placebo-controlled phase 2 trial including a long-term, open-label follow-up study
2017 · F. Muntoni, J. Buchbjerg, et al. · Neuromuscular Disorders · 1
MO20-2 Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)
2024 · K. Izutsu, D. Akahane, et al. · Annals of Oncology
PDF
O16-5 Epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 longer-term data
2024 · K. Izutsu, T. Kumode, et al. · Annals of Oncology
PDF
O13-3 Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
2023 · Koji Izutsu, Takahiro Kumode, et al. · Annals of Oncology
P.063 SUNFISH Part 1 results and Part 2 trial design in patients with type 2/3 spinal muscular atrophy (SMA) receiving risdiplam (RG7916)
2019 · C Campbell, E Mercuri, et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
PDF
Sma Therapies Ii and Biomarkers
2018 · E. Bertini, J. Day, et al. · Neuromuscular Disorders
A multinational, randomized, double-blind, placebo-controlled Phase 2 study to assess safety and efficacy of olesoxime in Type 2 or non-ambulatory Type 3 spinal muscular atrophy
2017 · J. Buchbjerg, E. Bertini, et al. · Neuromuscular Disorders
Works count: 22
Citation count: 457
H-index: 7
I10-index: 7
Year
Topic
Type